Please select the eligibility criteria that correspond to the clinical trial below.
Title: San Diego Bleeding Esophageal Varices Study
Brief Summary: In unselected cirrhotic patients with bleeding esophageal varices to compare the influence on mortality rate, duration of life, quality of life, and economic costs of treatment of:

* Emergency portacaval shunt, and
* Emergency and long-term endoscopic sclerotherapy.


Options:
A: Inclusion Criteria:

* Patients between 18 and 80 years old.
* Clinical criteria and/or analytical, ultrasound and/or liver biopsy consistent with the diagnosis of liver cirrhosis.
* Hematemesis or melenas within 7 days prior to study inclusion.
* Variceal bleeding. Endoscopic diagnosis:

  * Active variceal bleeding.
  * Clot or platelet cluster or,
  * Esophageal varices associated to red blood in esophagogastric lumen in the absence of other sources of bleeding.
* Patients with standard treatment for prevention of recurrence of variceal bleeding (EVL+B Blockers,Propanolol).
* Women of childbearing age should have a urine pregnancy test negative for 7 days before commencement of treatment and postmenopausal women must have amenorrhea for at least 12 months to be considered not fertile. Potential childbearing women and men must commit to use adequate contraception prior to joining the study and during it.
* Written informed consent to participate in the study.

Exclusion Criteria:

* Pregnancy or lactation
* Presence multiple hepatocellular carcinoma or only diameter\> 5 cm.
* Renal failure ( Creatinine \> 2 mg/dl)
* Advanced liver disfunction (Child Pugh \> 13 points)
* Contraindication for statins.
* Patients HIV treated with antiretroviral therapy.
* Pre-treatment with portosystemic shunt ( surgical or percutaneous).
* Bleeding due to gastric varices.
* Patients with total portal vein thrombosis or portal cavernomatosis.
* Patients previously treated with endoscopic variceal ligation and B- Blockers (before index episode).
* Patients previously treated with statins ( one month before the study).
B: Inclusion Criteria:

* Written informed consent
* Liver cirrhosis
* Portal vein thrombosis (degree of vessel obstruction \> 50%)
* History of variceal hemorrhage in the past 6 weeks (recent variceal bleeding has been controlled for at least 120 hours)

Exclusion Criteria:

* Uncontrolled active variceal bleeding
* Fibrotic cord of the portal vein
* Prior history of TIPS placement or shunt surgery or endoscopic ban ligation +NSBB
* Concomitant renal insufficiency
* Severe cardiopulmonary diseases
* Uncontrolled systemic infection or sepsis
* Malignancy or other serious medical illness which may reduce the life expectancy
* Contraindications for propranolol, such as asthma, insulin-dependent diabetes (with episodes of hypoglycemia), and peripheral vascular disease
* Contraindications for heparin or warfarin
* Contraindications for TIPS
C: Inclusion Criteria:

* Patients with portal hypertension caused by liver cirrhosis who presented with an acute or recent episode of gastroesophageal variceal bleeding and have previously received endoscopic treatments of ligation and cyanoacrylate. Diagnosis of liver cirrhosis or mixed cirrhosis was based on results of liver biopsy or biochemical tests and liver imaging by ultrasonography.
* The extent of the varices range from Moderate to Severe.
* The age of the patients range from 18 to 72 years old.

Exclusion Criteria:

* Patients who had other causes for portal hypertention(CTPV,Budd-Chiari syndrome,etc.)
* Patients with severe systemic disease (renal failure, heart failure,carcinoma other than liver cancer,etc.)
* Patients who had contraindications for ligation,sclerotherapy or cyanoacrylate.
* Patients who have previously received shunt or devascularization operation,TIPS.
* Patients who had portosystemic shunt according to the results of CT scan.
D: Inclusion Criteria:

* All patients with UGI bleeding (blood in the esophagus, stomach, or duodenum) who enter the emergency room or develop bleeding while in the hospital or are transferred from nearby hospitals and are suspected of having cirrhosis and BEV will be eligible for consideration (all comers).
* Those who are shown to have the findings of cirrhosis and esophageal varices that:

  * Are seen to be actively bleeding;
  * Have an adherent clot;
  * Have no other associated lesion that could reasonably account for bleeding of that magnitude (such as large gastric or duodenal varices, GU, DU, etc)
* Require 2 or more units of blood transfusion, will be included in the study.

Exclusion Criteria:

* None

Answer: D